

73SB-832SB

20 December 1973

Gerald L. Klerman, M.D.
Superintendent
Erich Lindemann Mental Health Center
Government Center
Boston, Massachusetts 02114

Dear Gerry:

I have heard of the work of your Committee at the FDA but was especially pleased to read the write-up in Psychiatric News. I found the missions of the Committee of considerable interest because the present methods of affecting change in regulatory policy do not allow for a regularized input from the academic community.

In this regard, I am taking the liberty of sending you copies of letters I sent to the FDA. There is much concern with problems of drug equivalence and bioavailability. EEG measures to record the central effects of psychoactive drugs and studies done in this laboratory and similar laboratories in St. Louis, Basel, and Göteborg provide optimism that these techniques may be useful in answering questions to which blood level measurements are now applied.

Should it be within the purview of the Committee, perhaps you could consider a review of the available data with an eye to undertaking collaborative studies.

My best regards for a successful new year.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF/cis
Encl.